Drug Trial Radar · NCT01916226
A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
682
Actual
Start
Aug 1, 2013
Primary completion
Oct 1, 2013
Study completion Oct 17, 2013
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs. cetirizine on allergic nasal and ocular symptoms and quality of life in adult subjects with SAR. It is hypothesized that FPNS provides greater nasal symptom relief than cetirizine. The primary measure used to test this hypothesis is the change from baseline over two weeks in reflective total nasal symptom score (rTNSS) compared between FPNS and cetirizine. Approximately 648 subjects will be randomized into a 1:1:1:1 ratio of treatment allocation across approximately twenty-five to thirty-five sites in the US during the 2013 fall allergy season. All subjects will be outpatients. The total duration of study will be approximately 21 days including 7 days of screening period, and 14 days of treatment period.
Conditions
- Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNSDrug
Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
FPNS PlaceboDrug
Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
CetirizineDrug
Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
Cetirizine PlaceboDrug
Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline (CFB) in the Individual AM Reflective Total Nasal Symptom Scores (rTNSS) Over the Entire Treatment PeriodTime frame: Baseline through the entire treatment period (2 weeks)
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Lenexa, Kansas
GSK Investigational Site
Overland Park, Kansas
GSK Investigational Site
Owensboro, Kentucky
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Bethesda, Maryland
GSK Investigational Site
North Dartmouth, Massachusetts
GSK Investigational Site
Ypsilanti, Michigan
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
Rolla, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Bellevue, Nebraska
GSK Investigational Site
Canton, Ohio
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Orangeburg, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Kerrville, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Waco, Texas
GSK Investigational Site
South Burlington, Vermont
GSK Investigational Site
Greenfield, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.